Oncoshot receives funding to additional broaden in India, Australia
Singaporean medical startup Oncoshot has scored an undisclosed funding via a pre-Collection A funding spherical led by Biofurmis and Qure.ai investor MassMutual Ventures.
Based mostly on a press launch, the funding will help the corporate’s additional enlargement into India and Australia.
There are 4 hospital networks in India and a few networks of over 20 hospitals in Oceania which might be about to arrange their respective nationwide public-private medical trial ecosystems like Singapore’s Project EISE. The latter makes use of Oncoshot’s medical trial matching platform to attach most cancers sufferers, healthcare professionals, and pharmaceutical and biotechnology firms.
It’s stated that medical trials worldwide lose round $35 billion every year because of inefficient processes in most cancers analysis and affected person recruitment.
Oncoshot has developed an answer to such points by enhancing the well being information of medical companions via AI and machine studying. Its federated information system securely hosts essential and delicate affected person information inside hospital premises and gives full safety, entry and management of analyses and insights to hospital directors.
Well being information web site Happiest Well being goes reside in India
Indian IT service and consultancy agency Happiest Minds Applied sciences has launched a brand new on-line repository of well being and wellness information and knowledge.
Known as Happiest Well being, the web site goals to offer “in-depth, credible, and reliable” info on well being and wellness, in line with a press assertion.
It can educate its viewers with breakthroughs and developments in well being and wellness, sourced from new analysis and research from associate world institutes. The portal can even put a highlight on new instruments for early analysis, in addition to consumer tales and feedback.
Furthermore, a panel of medical doctors and wellness consultants will contribute visitor essays and articles that provide distinctive views and attention-grabbing medical experiences.
“By means of Happiest Well being, we need to construct the significance of built-in medication, present helpful information via consultants on early analysis and evidence-based therapies and accomplish that with empathy and keenness,” stated Happiest Well being chairman Ashok Soota.
By subsequent 12 months, the web site will publish written and video content material in regional languages to cater to lower-tier cities in India. Happiest Well being can even launch a podcast, internet collection, and audio content material quickly.
Scientific trials in India affirm AI’s effectiveness in detecting referable glaucoma
Indian medical system maker Remidio Revolutionary Options has reported optimistic outcomes from separate medical trials of its AI resolution in detecting referable glaucoma.
Remidio provides an built-in screening resolution for referable glaucoma, a stage whereby the illness can nonetheless be higher managed via therapy. It consists of a fundus on cellphone, a retinal imaging system, and an AI algorithm for offline inferencing. The Medios Referable Glaucoma AI detects structural modifications within the optic nerve head and surrounding retinal nerve fibre layer.
Based on a press assertion, the entire detection course of solely takes 15 seconds.
The corporate just lately partnered with two native eye hospitals, Aravind Eye Hospital in Pondicherry and Narayana Nethralaya (NN) in Bangalore, to check its screening resolution.
Within the medical trial at NN, the AI algorithm was discovered to achieve a excessive sensitivity of 93.5% and excessive specificity of 85.4% in detecting referable glaucoma whereas early outcomes from the medical trial at Aravind confirmed the algorithm to additionally obtain excessive sensitivity and specificity of 91.3% and 91.67%, respectively.
The corporate famous that whereas therapy choices for managing referable glaucoma exist, easy screening checks are troublesome to search out. At current, glaucoma specialists are nonetheless conducting a collection of advanced investigations utilizing a number of units to identify referable glaucoma.
“Promising outcomes present that our AI can empower healthcare employees and normal ophthalmologists to make an goal screening analysis, particularly at centres missing refined diagnostic gear,” stated Dr Divya Rao, medical director and head of AI at Remidio.
